Your session is about to expire
← Back to Search
Latiglutenase for Celiac Disease
Study Summary
This trial is testing whether a new treatment can help people with Type 1 diabetes and celiac disease who are trying to follow a gluten-free diet.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current participant count of this trial?
"Indeed, the information on clinicaltrials.gov suggests that this medical trial is enrolling participants at present. It was first published in April 2021 and received a recent update in August 2022; 40 individuals are expected to partake from one clinic."
Who meets the criteria to join this research project?
"In this clinical trial, 40 individuals suffering from celiac disease and type 1 diabetes between 18-80 years old are being recruited. The primary prerequisites for applicants are: a confirmed CD diagnosis; presence of antibodies confirming T1D status; ongoing consumption of gluten free diet (for 12 months or more); occurrence of at least one moderate symptom in the last 28 days; consent to take study treatment every day, and agreement to sign informed consent form."
What harmful effects could arise from taking Latiglutenase IMGX003?
"It is estimated that Latiglutenase IMGX003 has a score of 2 for safety on a scale from 1 to 3 because this trial is currently in Phase 2, indicating there are some supporting data regarding its security but no evidence yet backing up its efficacy."
Does this research effort introduce a new concept or methodology?
"The first clinical trials surrounding Latiglutenase IMGX003 began in 2019, led by Immunogenics, LLC. After its initial Phase 1 study with 120 participants, the drug gained approval to proceed into Phase 2 testing. At present, there are two active studies of this medication occurring across one nation's two major cities."
Are there still opportunities for participants to join this clinical experiment?
"Per the information on clinicaltrials.gov, this investigation is currently accepting volunteers and was first posted April 6th 2021 with a recent edit occurring August 2nd 2022."
Does the eligibility for this research extend to seniors above 75 years of age?
"This medical study seeks out individuals over 18 yet below 80 years of age to be enrollees."
Could you provide information on other experiments that have utilized Latiglutenase IMGX003?
"Presently, two clinical trials are deployed to investigate the effects of Latiglutenase IMGX003. Neither of these studies is in Phase 3 yet. The research sites for this treatment are based mainly in Palo Alto, California but there exist other locations as well conducting similar investigations."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Stanford University: < 24 hours
Average response time
- < 1 Day
Share this study with friends
Copy Link
Messenger